Merch Store

-HZNP’s Tepezza drug for thyroid eye disease showed stronger than expected 1Q20 growth

-Even after a post-1Q20 report jump, HZNP shares still reasonable value vs growth potential

-Both Tepezza an Krystexxa medicines show promise; stock could rise up to 30%

If the stock market recovery is for real, and we think it is, some investors might move away from more defensive equities such as healthcare shares. That’s understandable, but all portfolios can benefit from balance and diversity, so don’t eschew healthcare stocks completely.

That’s doubly true if the healthcare stock in question appears to be on the cusp of fast growth and potentially turning sustainably profitable.  And what if it has the only U.S. Food & Drug Administration (FDA) approved drug to treat the debilitating thyroid eye disease (TED)? TED is a rare, progressive and vision-threatening autoimmune disease that heretofore has been treated with steroids and surgery.  Throw in a promising pipeline and you are describing Horizon Therapeutics Plc (HZNP).

Source: FS Insight, Bloomberg
The Ireland-domiciled biopharma company specializes in treatments—some of the orphan drugs for rare diseases—and currently has 11 approved medicines, for diseases such as gout, urea cycle disorders...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

If you are already a member at FS Insight, please Sign In If you don’t have a subscription to FS Insight yet, you can sign up below.

Disclosures (show)
complimentary articles / month
FS Insight Guest PASS

Our FS Insight Guest PASS offers you 3 complimentary research reports every month.

You can unlock 2 more articles by joining our newsletter!

You have reached the maximum amount of complimentary reports for this month.
You will receive 3 more complimentary reports as of the 1st of June.

Don't Miss Out
First Month Free